Adalimumab is an anti-TNF (anti-tumour necrosis factor) drug. It blocks the action of TNF proteins and so reduces inflammation.
Find out more
It’s available for people with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, and for children with juvenile idiopathic arthritis (JIA).
It’s usually given as a 40 mg injection once every 2 weeks.
The most common side-effects are reactions at the injection site, such as redness, swelling or pain. It can also make you more likely to develop infections.